Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Cited by (1,000)

Items 301–400 of 1,000

1. Gene-expression profiling to predict responsiveness to immunotherapy
   Nigel Balfour Jamieson, Ajay V. Maker · 2016 · Cancer Gene Therapy
2. Dual TGF‐β and PD‐1 blockade synergistically enhances MAGE‐A3‐specific CD8+ T cell response in esophageal squamous cell carcinoma
   Xinfeng Chen, Liping Wang, Pupu Li, Mengjia Song, Guohui Qin, Qun Gao, Zhen Zhang, Dongli Yue, Dan Wang, Shufeng Nan et al. · 2018 · International Journal of Cancer
3. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
   Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Olivia. Lu, Karolina Palucka, Josue A. Samayoa, Stefani Spranger, Sarah E. Warren, Kwok‐Kin Wong et al. · 2019 · Journal for ImmunoTherapy of Cancer
4. Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
   Mahmoud S. Alghamri, Brandon L. McClellan, Carson S. Hartlage, Santiago Haase, Syed Mohd Faisal, Rohit Thalla, Ali A. Dabaja, Kaushik Banerjee, Stephen V. Carney, Anzar Mujeeb et al. · 2021 · Frontiers in Pharmacology
5. Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
   Dimitrios C. Ziogas, Charalampos Theocharopoulos, Peter Lialios, Dimitra Foteinou, Ioannis‐Alexios Koumprentziotis, Georgios Xynos, Helen J Gogas · 2023 · Cancers
6. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
   Dongxu Wang, Jianzhen Lin, Xu Yang, Junyu Long, Yi Bai, Xiaobo Yang, Yilei Mao, Xinting Sang, Samuel Seery, Haitao Zhao · 2019 · Journal of Hematology & Oncology
7. The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance
   Renee B. Chang, Gregory Lawrence Beatty · 2020 · Journal of Leukocyte Biology
8. Association ofMUC16Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
   Lei Zhang, Xiaohong Han, Yuankai Shi · 2020 · JAMA Network Open
9. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells
   Young-Ho Lee, Hyeong Ji Lee, Hyung Cheol Kim, Yujean Lee, Su Kyung Nam, Cedric Hupperetz, Jennifer S. Y. Ma, Xinxin Wang, Oded Singer, Won Seog Kim et al. · 2021 · Molecular Therapy
10. Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
    Kevin Park, Mysore S. Veena, Daniel Sanghoon Shin · 2022 · Frontiers in Cell and Developmental Biology
11. TIM-3 pathway dysregulation and targeting in cancer
    Amer Methqal Zeidan, Rami S. Komrokji, Andrew Mark Brunner · 2020 · Expert Review of Anticancer Therapy
12. Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
    Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros S Ardavanis, Graham Pawelec et al. · 2017 · Journal for ImmunoTherapy of Cancer
13. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
    Young–Jin Choi, Su Hyun Seok, Hong Yeol Yoon, Ju Hee Ryu, Ick Chan Kwon · 2024 · Advanced Drug Delivery Reviews
14. Dacarbazine nanoparticle topical delivery system for the treatment of melanoma
    Abdul Hafeez, Imran Ahmed Kazmi · 2017 · Scientific Reports
15. Emerging biomarkers for immune checkpoint inhibition in lung cancer
    George Cyriac, Leena Gandhi · 2018 · Seminars in Cancer Biology
16. A good start of immunotherapy in esophageal cancer
    Qian Zhao, Jin-Ming Yu, Xue Meng · 2019 · Cancer Medicine
17. Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease
    Kimura, Kimitoshi, Subramanian, Ayshwarya, Yin, Zhuoran, Khalilnezhad, Ahad, Wu, Yufan, He, Danyang, Dixon, Karen O., Chitta, Udbhav Kasyap, Ding, Xiaokai, Adhikari, Niraj et al. · 2025 · Nature
18. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells
    Ailin Li, Hampartsoum B. Barsoumian, Jonathan E. Schoenhals, Taylor R. Cushman, Mauricio S. Caetano, Xiaohong Wang, David R. Valdecanas, Sharareh Niknam, Ahmed I. A. Younes, Guang Li et al. · 2018 · Cancer Letters
19. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
    Shusuke Kawashima, Takashi Inozume, Masahito Kawazu, Toshihide Ueno, Joji Nagasaki, Etsuko Tanji, Akiko Honobe‐Tabuchi, Takehiro Ohnuma, Tatsuyoshi Kawamura, Yoshiyasu Umeda et al. · 2021 · Journal for ImmunoTherapy of Cancer
20. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
    Harriet M. Kluger, J. Carl Barrett, Justin F. Gainor, Omid Hamid, Michael E. Hurwitz, Theresa M. LaVallee, Rebecca Anne Moss, Roberta Zappasodi, Ryan Joseph Sullivan, Hussein A. Tawbi et al. · 2023 · Journal for ImmunoTherapy of Cancer
21. HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas
    J. Lechien, G. Descamps, I. Seminerio, S. Furgiuele, D. Dequanter, F. Mouawad, C. Badoual, F. Journé, S. Saussez · 2020 · Cancers
22. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
    Piera Federico, Angelica Petrillo, Pasqualina Giordano, Davide Bosso, Antonietta Fabbrocini, Margaret Ottaviano, Mario Rosanova, Antonia Silvestri, Andrea Tufo, Antonio Cozzolino et al. · 2020 · Cancers
23. The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
    Bonnie L. Russell, Selisha Ann Sooklal, Sibusiso Tebogo Malindisa, Lembelani Jonathan Daka, Monde McMillan Ntwasa · 2021 · Frontiers in Oncology
24. Molecular patterns of resistance to immune checkpoint blockade in melanoma
    Martin Lauss, Bengt Phung, Troels Holz Borch, Katja Harbst, Kamila K. Kaminska, Anna Ebbesson, Ingrid A. Hedenfalk, Joan Yuan, Kari Nielsen, Christian Ingvar et al. · 2024 · Nature Communications
25. T‐cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer
    Jianfeng Liu, Si‐Rui Ma, Liang Mao, Lin‐Lin Bu, Guang‐Tao Yu, Yicun Li, Cong‐Fa Huang, Wei‐Wei Deng, Ashok B. Kulkarni, Wen‐Feng Zhang et al. · 2017 · Molecular Oncology
26. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis
    Hualin Zhang, Yang Song, Huimin Yang, Zhiyan Liu, Lifen Gao, Xiaohong Liang, Chunhong Ma · 2018 · Oncogene
27. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
    Qingyang Xiao, André Nobre, Pilar Piñeiro, Miguel‐Ángel Berciano‐Guerrero, Emilio Alba, Manuel Cobo, Volker Martin Lauschke, Isabel Barragán · 2020 · Journal of Clinical Medicine
28. Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
    Yefang Lao, Daoming Shen, Weili Zhang, Rui He, Min Jiang · 2022 · Cancers
29. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
    Ronan Flippot, Bernard J. Escudier, Laurence K. Albiges · 2018 · Drugs
30. Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine
    Ahmad A. Tarhini, Ragini Reiney Kudchadkar · 2018 · Cancer Treatment Reviews
31. Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers
    Maria Davern, Joanne Lysaght · 2020 · Cancer Letters
32. Molecular subtype identification and prognosis stratification by a metabolism-related gene expression signature in colorectal cancer
    Dagui Lin, Wenhua Fan, Rongxin Zhang, Enen Zhao, Pansong Li, Wenhao Zhou, Jianhong Peng, Li Li · 2021 · Journal of Translational Medicine
33. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
    Bin Wang, Han Yin, Yuyu Zhang, Qin Zhao, Huanhuan Wang, Jinlong Wei, Lingbin Meng, Ying Xin, Xin Mei Jiang · 2023 · Cell & Bioscience
34. Beyond T cell exhaustion: TIM-3 regulation of myeloid cells
    Karen Olivia Dixon, Gonzalo Fernandez Lahore, Vijay Kumar Kuchroo · 2024 · Science Immunology
35. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non‐small‐cell lung cancer patients
    Chufeng Zhang, Jixin Wang, Zhongwen Sun, Yufeng Cao, Zhengshuai Mu, Xuming Ji · 2021 · Cancer Science
36. Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)
    Yu Yu, Jiuwei Cui · 2018 · Oncology Letters
37. Combination immunotherapy strategies for glioblastoma
    Hok Yee Chan, John Hyunkuk Choi, Christina Jackson, Michael K. Lim · 2021 · Journal of Neuro-Oncology
38. Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies
    Binghan Zhou, Yuan Gao, Peng Zhang, Qian Chu · 2021 · Frontiers in Immunology
39. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
    Uasim Harkus, Miriam Wankell, Pranavan Palamuthusingam, Craig McFarlane, Lionel Hebbard · 2022 · Seminars in Cancer Biology
40. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
    Xingyu Chen, Lixiang Feng, Yujing Huang, Yi Wu, Na Xie · 2022 · Cancers
41. Biomarkers of response to immune checkpoint blockade in cancer treatment
    Takeo Fujii, Aung Naing, Christian D. Rolfo, Joud Hajjar · 2018 · Critical Reviews in Oncology/Hematology
42. EZH2 Inhibition: A Promising Strategy to Prevent Cancer Immune Editing
    Ning Kang, Mark Eccleston, Pier‐Luc Clermont, Maryam Latarani, David Kingsley Male, Yuzhuo Z. Wang, Francesco Crea · 2020 · Epigenomics
43. Emerging Role of Extracellular Vesicles in Immune Regulation and Cancer Progression
    Sonam Mittal, Prachi Gupta, Pradeep Chaluvally–Raghavan, Sunila Pradeep · 2020 · Cancers
44. Immune Aging and Immunotherapy in Cancer
    Melanie Kaiser, Maria Donatella Semeraro, Markus Herrmann, Gudrun Absenger, Armin Gerger, Wilfried Renner · 2021 · International Journal of Molecular Sciences
45. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
    Christopher Aled Chamberlain, Eric Bennett, Anders Handrup Kverneland, Inge Marie Svane, Marco Donia, Özcan Met · 2022 · Molecular Therapy — Oncolytics
46. Tumor-associated macrophage-related strategies for glioma immunotherapy
    Fansong Tang, Yuelong Wang, Yunhui Zeng, Anqi Xiao, Aiping Tong, Jianguo Xu · 2023 · npj Precision Oncology
47. The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer
    Sophie Otter, Jayanta Chatterjee, Alexandra Stewart, Agnieszka Michael · 2019 · Clinical Oncology
48. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
    Maureen L. Drakes, Swati Mehrotra, Monica Aldulescu, Ronald K. Potkul, Yueying Liu, Anne Grisoli, Cara Joyce, Timothy E. O’Brien, Mary Sharon Stack, Patrick J. Stiff · 2018 · Journal of Ovarian Research
49. Acquired mechanisms of immune escape in cancer following immunotherapy
    Julian Bryan Iorgulescu, David A. Braun, Giacomo Oliveira, Derin B. Keskin, Catherine J. Wu · 2018 · Genome Medicine
50. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions
    Francesca Romana Mariotti, Linda Quatrini, Enrico Munari, Paola Vacca, Lorenzo Moretta · 2019 · Frontiers in Immunology
51. Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma
    Zenan Wang, Zhan Wang, Binghao Li, Shengdong Wang, Tao Chen, Zhaoming Ye · 2019 · Frontiers in Immunology
52. Immune oncology, immune responsiveness and the theory of everything
    Tolga Turan, Deepti Kannan, Maulik R Patel, James Matthew Barnes, Sonia G. Tanlimco, Rongze Olivia. Lu, Kyle D. Halliwill, Sarah Kongpachith, Douglas E. Kline, Wouter Hendrickx et al. · 2018 · Journal for ImmunoTherapy of Cancer
53. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment
    I‐Ying Kuo, You-En Yang, Pei‐Shan Yang, Yu-Jou Tsai, Hong‐Tai Tzeng, Hung‐Chi Cheng, Wan‐Ting Kuo, Wu‐Chou Su, Chih‐Peng Chang, Yi‐Ching Wang · 2021 · Theranostics
54. Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer
    Daniel E. Meyers, Paul Bryan, Shantanu Otto Banerji, Don G. Morris · 2018 · Current Oncology
55. Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
    Bo‐Kyeong Jung, Hae Young Ko, Hyunji Kang, JinWoo Hong, Hyo Min Ahn, Youjin Na, Hyeongi Kim, Jin Su Kim, Chae‐Ok Yun · 2020 · Journal for ImmunoTherapy of Cancer
56. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
    Kimiharu Takamatsu, Nobuyuki Tanaka, Kyohei Hakozaki, Ryohei Takahashi, Yu Teranishi, Tetsushi Murakami, Ryohei Kufukihara, Naoya Niwa, Shuji Mikami, Toshiaki Shinojima et al. · 2021 · Nature Communications
57. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions
    Joachim Stoltenborg Granhøj, Agnete W.P. Jensen, Mario Presti, Özcan Met, Inge Marie Svane, Marco Donia · 2022 · Expert Opinion on Biological Therapy
58. Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
    Pottayil G. Sasikumar, Murali Ramachandra · 2022 · Frontiers in Immunology
59. Nanocarriers for cancer nano-immunotherapy
    Isra Rana, Jaeeun Oh, Juwon Baig, Jeong Hyun Moon, Sejin Son, Jutaek Nam · 2022 · Drug Delivery and Translational Research
60. Dacarbazine-Loaded Hollow Mesoporous Silica Nanoparticles Grafted with Folic Acid for Enhancing Antimetastatic Melanoma Response
    Qianqian Liu, Nan Xu, Liping Liu, Jun Li, Yamin Zhang, Chen Shen, Khurram Shezad, Lianbin Zhang, Jintao Zhu, Juan Tao · 2017 · ACS Applied Materials & Interfaces
61. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment
    Daisuke Umezu, Nana Okada, Yukimi Sakoda, Keishi Adachi, Toshiyasu Ojima, Hiroki Yamaue, Masatoshi Eto, Koji Tamada · 2018 · Cancer Immunology Immunotherapy
62. Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
    Ahronian, Leanne G., Corcoran, Ryan B. · 2017 · Genome Medicine
63. Next generation immune-checkpoints for cancer therapy
    Chiara Donini, Lorenzo D’Ambrosio, Giovanni Grignani, Massimo Aglietta, Dario Sangiolo · 2018 · Journal of Thoracic Disease
64. Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance
    Ting Jiang, Xisha Chen, Xingcong Ren, Jinming Yang, Yan Cheng · 2021 · Drug Resistance Updates
65. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models
    Kosaku Mimura, Ley‐Fang Kua, Jin-Fen Xiao, Bernadette Reyna Asuncion, Yuko Nakayama, Nicholas L. X. Syn, Zul Fazreen, Richie Chuan Teck Soong, Koji Kono, Wei Peng Yong · 2021 · Gastric Cancer
66. The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma
    Madison K. Ernst, Alessio Giubellino · 2022 · Biomedicines
67. Learning from PD-1 Resistance: New Combination Strategies
    Xia Bu, Kathleen Margaret Mahoney, Gordon James Freeman · 2016 · Trends in Molecular Medicine
68. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination
    Éléonore De Guillebon, Antoine Dardenne, Antonin Saldmann, Sylvie Séguier, Thi Tran, Léa Paolini, Célèste Lebbé, Éric Tartour · 2020 · International Journal of Cancer
69. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer
    Lihua Liu, Mi Ae Lim, Seung‐Nam Jung, Chan Oh, Ho-Ryun Won, Yan Jin, Yudan Piao, Hae Jong Kim, Jae Won Chang, Bon Seok Koo · 2021 · Phytomedicine
70. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
    Zhuohong Yan, Chunmao Wang, Jinghong Wu, Jinghui Wang, Teng Ma · 2025 · Molecular Biomedicine
71. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity
    Gerhard Hamilton, Barbara Rath · 2017 · Expert Opinion on Biological Therapy
72. Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma
    Abhishek Dinkarnath Garg, Lien Vandenberk, Matthias Van Woensel, Jochen Belmans, Marco B.E. Schaaf, Louis Boon, Steven De Vleeschouwer, Patrizia Agostinis · 2017 · OncoImmunology
73. Significance of TIM3 expression in cancer: From biology to the clinic
    Cinzia Solinas, Pushpamali De Silva, D Bron, Karen E Willard-Gallo, Dario Sangiolo · 2019 · Seminars in Oncology
74. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth
    Chimera Lyle, Sean Richards, Kei Yasuda, Marc Arthur Napoleon, Joshua Walker, Nkiruka V. Arinze, Mostafa Belghasem, Irva Vellard, Wenqing Yin, Jonathan D. Ravid et al. · 2019 · Scientific Reports
75. Immunotherapy for hepatocellular carcinoma: Recent advances and future targets
    Su Jong Yu · 2023 · Pharmacology & Therapeutics
76. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair
    Akira Ooki, Hiroki Osumi, Koichiro Yoshino, Kensei Yamaguchi · 2024 · Gastric Cancer
77. mTOR Signalling in Head and Neck Cancer: Heads Up
    Fiona H. Tan, Yuchen Bai, P. Saintigny, C. Darido · 2019 · Cells
78. Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.
    G. Hanna, Hong-Ye Liu, Robert E. Jones, A. Bacay, P. Lizotte, E. Ivanova, M. Bittinger, Megan E. Cavanaugh, Amanda J. Rode, J. Schoenfeld et al. · 2017 · Oral Oncology
79. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies
    Marc C. Pulanco, Anne Tranberg Madsen, Ankit Tanwar, Devin T. Corrigan, Xingxing Zang · 2023 · Cellular and Molecular Immunology
80. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia
    Liuluan Zhu, Yaxian Kong, Jianhong Zhang, David F. Claxton, William Christopher Ehmann, Witold B. Rybka, Neil David Palmisiano, Ming Wang, Bei Jia, Michael G. Bayerl et al. · 2017 · Journal of Hematology & Oncology
81. Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype
    Ashvin R. Jaiswal, Arthur J. Liu, Shivanand Pudakalakatti, Prasanta Dutta, Priyamvada Jayaprakash, Todd Bartkowiak, Casey R. Ager, Zhiqiang Wang, Alexandre Reuben, Zachary Aaron Cooper et al. · 2020 · Cancer Immunology Research
82. Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells
    Beavis, Paul A., Henderson, Melissa A., Giuffrida, Lauren, Davenport, Alexander J., Petley, Emma V., House, Imran G., Lai, Junyun, Sek, Kevin, Milenkovski, Nicole, John, Liza B. et al. · 2018 · Cancer Immunology Research
83. PD-1 says goodbye, TIM-3 says hello
    Diana Romero · 2016 · Nature Reviews Clinical Oncology
84. Harnessing Tumor Evolution to Circumvent Resistance
    Katherine Lee McNamara, Christina N. Curtis · 2018 · Trends in Genetics
85. Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
    Soumaya Karaki, Marie Anson, Thi Tran, Delphine Giusti, Charlotte Blanc, Stéphane Marie. Oudard, Éric Tartour · 2016 · Vaccines
86. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
    Michael Friedrich, Simon Jasinski‐Bergner, Maria‐Filothei Lazaridou, Karthikeyan Subbarayan, Chiara Massa, Sandy Tretbar, Anja Müeller, Diana Handke, Katharina Biehl, Jürgen Bukur et al. · 2019 · Cancer Immunology Immunotherapy
87. Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade
    Linan Fang, Dalam Ly, Sisi Wang, Jong Bok Lee, Hyeonjeong Kang, Hao Xu, Junlin Yao, Ming‐Sound Tsao, Wei Liu, Zhang Li · 2019 · Journal of Experimental & Clinical Cancer Research
88. Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
    Jake S. O’Donnell, Mark John Smyth, Michele W.L. Teng · 2016 · Genome Medicine
89. Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer
    Tamara Muliaditan, James W. Opzoomer, Jonathan Caron, Mary Okesola, Paris Kosti, Sharanpreet Kall Lall, Mieke Van Hemelrijck, Francesco Dazzi, Andrew N.J. Tutt, Anita E. Grigoriadis et al. · 2018 · Clinical Cancer Research
90. A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer
    Xi Li, Rouzheng Wang, Peiwen Fan, Xuan Yao, Ling Qin, Yanchun Peng, Miaomiao Ma, Neil Asley, Xuimei Chang, Yaning Feng et al. · 2019 · Frontiers in Oncology
91. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy
    Xianhui Chen, Shuai Yang, Si Li, Yun Qu, Hsuan-Yao Wang, Jiangyue Liu, Zachary Spencer Dunn, Gunce E. Cinay, Melanie A. MacMullan, Fangheng Hu et al. · 2021 · Molecular Therapy — Oncolytics
92. A SERS microfluidic platform for targeting multiple soluble immune checkpoints
    Kamil Reza Khondakar, Abu Ali Ibn Sina, Alain Wuethrich, Yadveer S. Grewal, Christopher B. Howard, Darren J. Korbie, Matt Trau · 2018 · Biosensors and Bioelectronics
93. Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer
    Yue Yu, Xiaopeng Ma, Yanjuan Zhang, Yun Zhang, Jianming Ying, Wen Zhang, Qiaofeng Zhong, Aiping Zhou, Yixin Zeng · 2019 · Journal of Cancer
94. Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors
    Hollebecque, Antoine, Chung, Hyun C., de Miguel, Maria J., Italiano, Antoine, Machiels, Jean-Pascal, Lin, Chia-Chi, Dhani, Neesha C., Peeters, Marc, Moreno, Victor, Su, Wu-Chou et al. · 2021 · Clinical Cancer Research
95. Nanozyme-Based Enhanced Cancer Immunotherapy
    Ngoc Man Phan, Thanh Loc Nguyen, Jaeyun Kim · 2022 · Tissue Engineering and Regenerative Medicine
96. An optimal portfolio of photothermal combined immunotherapy
    Wenfeng Zeng, Zimu Li, Hongzhong Chen, Xiaowei Zeng, Lin Mei · 2022 · Cell Reports Physical Science
97. Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection
    Karla A. Ruiz-Ceja, Yolanda I. Chirino · 2017 · Biomedicine & Pharmacotherapy
98. Overcoming Immunological Resistance Enhances the Efficacy of a Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma
    Mahboubeh Yazdanifar, Ru Zhou, Priyanka Grover, Chandra Williams, Mukulika Bose, Laura Jeffords Moore, Shu-ta Wu, Richard Chi, John Maher, Didier Dreau et al. · 2019 · Cells
99. Emerging immunotherapies for metastasis
    Sarah C. Edwards, Wilma H. M. Hoevenaar, Seth B. Coffelt · 2020 · British Journal of Cancer
100. Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
     Jason Adhikaree, Julia Moreno-Vicente, Aanchal Preet Kaur, Andrew Mark Jackson, Poulam M. Patel · 2020 · Cells